natgillin/translations-raw huggingface dataset:
EU/1/96/022/033 - ZYPREXA - 15 mg - coated tablets - 70 tablets, per box. 
EU/1/96/022/033 - ZYPREXA - 15 mg - obložene tablete - 70 tablet na škatlo.
EU/1/96/022/034 - ZYPREXA - 20 mg - coated tablets - 70 tablets, per box. 
EU/1/96/022/034 - ZYPREXA - 20 mg - obložene tablete - 70 tablet na škatlo.
NAME OF THE MEDICINAL PRODUCT ZYPREXA 2.5 mg coated tablets Olanzapine 
IME ZDRAVILA ZYPREXA 2,5 mg obložene tablete olanzapin
EU/1/96/022/035 - ZYPREXA - 2.5 mg - coated tablets - 98 tablets, per box. 
EU/1/96/022/035 - ZYPREXA - 2,5 mg - obložene tablete - 98 tablet na škatlo.
EU/1/96/022/009 - ZYPREXA - 10 mg - coated tablets - 28 tablets, per box. 
EU/1/96/022/009 - ZYPREXA - 10 mg - obložene tablete - 28 tablet na škatlo.
EU/1/96/022/023 - ZYPREXA - 2.5 mg - coated tablets - 35 tablets, per box. 
EU/1/96/022/023 - ZYPREXA - 2,5 mg - obložene tablete - 35 tablet na škatlo.
NAME OF THE MEDICINAL PRODUCT ZYPREXA 10 mg coated tablets Olanzapine 
IME ZDRAVILA ZYPREXA 10 mg obložene tablete olanzapin
EU/1/96/022/012 - ZYPREXA - 15 mg - coated tablets - 28 tablets, per box. 
EU/1/96/022/012 - ZYPREXA - 15 mg - obložene tablete - 28 tablet na škatlo.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA 7.5 mg COATED TABLETS: BLISTER FOIL LABEL 
ZYPREXA 7,5 mg OBLOŽENE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high 
14 Opazovano pri osnovnih normalnih ravneh na tešče (< 1,016 mmol/l), ki so se povišale na visoke (≥ 1,467 mmol/l) in spremembe v ravneh trigliceridov na tešče z mejnih osnovnih vrednosti
EU/1/96/022/025 - ZYPREXA - 7.5 mg - coated tablets - 35 tablets, per box. 
EU/1/96/022/025 - ZYPREXA - 7,5 mg - obložene tablete - 35 tablet na škatlo.
EU/1/96/022/040 - ZYPREXA - 20 mg - coated tablets - 98 tablets, per box. 
EU/1/96/022/040 - ZYPREXA - 20 mg - obložene tablete - 98 tablet na škatlo.
Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma. 
vznemirjenost/nasilnost, dizartrijo, različne ekstrapiramidne simptome in motnje zavesti v razponu od sedacije do kome.
Temporal association of treatment with IM olanzapine with hypotension, bradycardia, respiratory depression and death has been very rarely (< 0.01 %) reported particularly in patients who have received benzodiazepines and/or other antipsychotics (see section 4.8). 
Zelo redko (< 0,01 %) so zlasti pri bolnikih, ki so prejemali benzodiazepine in/ali druge antipsihotike, poročali o časovni povezavi zdravljenja z i.m.
EU/1/96/022/002 - ZYPREXA - 2.5 mg - coated tablets - 28 tablets, per box. 
EU/1/96/022/002 - ZYPREXA - 2,5 mg - obložene tablete - 28 tablet na škatlo.
EU/1/96/022/028 - ZYPREXA - 20 mg - coated tablets - 35 tablets, per box. 
EU/1/96/022/028 - ZYPREXA - 20 mg - obložene tablete - 35 tablet na škatlo.
EU/1/96/022/032 - ZYPREXA - 10 mg - coated tablets - 70 tablets, per box. 
EU/1/96/022/032 - ZYPREXA - 10 mg - obložene tablete - 70 tablet na škatlo.
How to store ZYPREXA 
Shranjevanje zdravila ZYPREXA
EU/1/96/022/019 - ZYPREXA - 2.5 mg - coated tablets - 56 tablets, per box. 
EU/1/96/022/019 - ZYPREXA - 2,5 mg - obložene tablete - 56 tablet na škatlo.
EU/1/96/022/004 - ZYPREXA - 5 mg - coated tablets - 28 tablets, per box. 
EU/1/96/022/004 - ZYPREXA - 5 mg - obložene tablete - 28 tablet na škatlo.
Other common side effects(may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males. 
Drugi pogosti neželeni učinki (lahko prizadenejo do 1 od 10 bolnikov) vključujejo spremembe v ravneh nekaterih krvnih celic, maščob v krvnem obtoku in v začetnih obdobjih zdravljenja, začasno povišanje jetrnih encimov, zvišanja v ravni sladkorjev v krvi in urinu, zvišanja v ravni sečne kisline in kreatin-fosfokinaze v krvi, večji občutek lakote, omotico, nemirnost, tresenje, nenavadne gibe
EU/1/96/022/014 - ZYPREXA - 20 mg - coated tablets - 28 tablets, per box. 
EU/1/96/022/014 - ZYPREXA - 20 mg - obložene tablete - 28 tablet na škatlo.
ZYPREXA 10 mg coated tablets Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4117”. 
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4117”.
EU/1/96/022/027 - ZYPREXA - 15 mg - coated tablets - 35 tablets, per box. 
EU/1/96/022/027 - ZYPREXA - 15 mg - obložene tablete - 35 tablet na škatlo.
EU/1/96/022/038 - ZYPREXA - 10 mg - coated tablets - 98 tablets, per box. 
EU/1/96/022/038 - ZYPREXA - 10 mg - obložene tablete - 98 tablet na škatlo.
EU/1/96/022/030 - ZYPREXA - 5 mg - coated tablets - 70 tablets, per box. 
EU/1/96/022/030 - ZYPREXA - 5 mg - obložene tablete - 70 tablet na škatlo.
EU/1/96/022/022 - ZYPREXA - 20 mg - coated tablets - 56 tablets, per box. 
EU/1/96/022/022 - ZYPREXA - 20 mg - obložene tablete - 56 tablet na škatlo.
NAME OF THE MEDICINAL PRODUCT ZYPREXA 5 mg coated tablets Olanzapine 
IME ZDRAVILA ZYPREXA 5 mg obložene tablete olanzapin
EU/1/96/022/024 - ZYPREXA - 5 mg - coated tablets - 35 tablets, per box. 
EU/1/96/022/024 - ZYPREXA - 5 mg - obložene tablete - 35 tablet na škatlo.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA 2.5 mg COATED TABLETS: BLISTER FOIL LABEL 
ZYPREXA 2,5 mg OBLOŽENE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
EU/1/96/022/039 - ZYPREXA - 15 mg - coated tablets - 98 tablets, per box. 
EU/1/96/022/039 - ZYPREXA - 15 mg - obložene tablete - 98 tablet na škatlo.
EU/1/96/022/026 - ZYPREXA - 10 mg - coated tablets - 35 tablets, per box. 
EU/1/96/022/026 - ZYPREXA - 10 mg - obložene tablete - 35 tablet na škatlo.
EU/1/96/022/021 - ZYPREXA - 15 mg - coated tablets - 56 tablets, per box. 
EU/1/96/022/021 - ZYPREXA - 15 mg - obložene tablete - 56 tablet na škatlo.
EU/1/96/022/036 - ZYPREXA - 5 mg - coated tablets - 98 tablets, per box. 
EU/1/96/022/036 - ZYPREXA - 5 mg - obložene tablete - 98 tablet na škatlo.
EU/1/96/022/010 - ZYPREXA - 10 mg - coated tablets - 56 tablets, per box. 
EU/1/96/022/010 - ZYPREXA - 10 mg - obložene tablete - 56 tablet na škatlo.
NAME OF THE MEDICINAL PRODUCT ZYPREXA 15 mg coated tablets Olanzapine 
IME ZDRAVILA ZYPREXA 15 mg obložene tablete olanzapin
EU/1/96/022/020 - ZYPREXA - 5 mg - coated tablets - 56 tablets, per box. 
EU/1/96/022/020 - ZYPREXA - 5 mg - obložene tablete - 56 tablet na škatlo.
EU/1/96/022/004 28 coated tablets EU/1/96/022/024 35 coated tablets EU/1/96/022/020 56 coated tablets EU/1/96/022/030 70 coated tablets EU/1/96/022/036 98 coated tablets 
EU/1/96/022/004 28 obloženih tablet EU/1/96/022/024 35 obloženih tablet EU/1/96/022/020 56 obloženih tablet EU/1/96/022/030 70 obloženih tablet EU/1/96/022/036 98 obloženih tablet
EU/1/96/022/014 28 coated tablets EU/1/96/022/028 35 coated tablets EU/1/96/022/022 56 coated tablets EU/1/96/022/034 70 coated tablets EU/1/96/022/040 98 coated tablets 
EU/1/96/022/014 28 obloženih tablet EU/1/96/022/028 35 obloženih tablet EU/1/96/022/022 56 obloženih tablet EU/1/96/022/034 70 obloženih tablet EU/1/96/022/040 98 obloženih tablet
Hydrochloric acid. 
Rumeni liofilizirani prašek.
How to store ZYPREXA 6. 
Kako uporabljati zdravilo ZYPREXA
EU/1/96/022/01128 coated tablets EU/1/96/022/025 35 coated tablets EU/1/96/022/006 56 coated tablets EU/1/96/022/031 70 coated tablets EU/1/96/022/037 98 coated tablets 
EU/1/96/022/011 28 obloženih tablet EU/1/96/022/025 35 obloženih tablet EU/1/96/022/006 56 obloženih tablet EU/1/96/022/031 70 obloženih tablet EU/1/96/022/037 98 obloženih tablet
EU/1/96/022/012 28 coated tablets EU/1/96/022/027 35 coated tablets EU/1/96/022/021 56 coated tablets EU/1/96/022/033 70 coated tablets EU/1/96/022/039 98 coated tablets 
EU/1/96/022/012 28 obloženih tablet EU/1/96/022/027 35 obloženih tablet EU/1/96/022/021 56 obloženih tablet EU/1/96/022/033 70 obloženih tablet EU/1/96/022/039 98 obloženih tablet
EU/1/96/022/009 28 coated tablets EU/1/96/022/026 35 coated tablets EU/1/96/022/010 56 coated tablets EU/1/96/022/032 70 coated tablets EU/1/96/022/038 98 coated tablets 
EU/1/96/022/009 28 obloženih tablet EU/1/96/022/026 35 obloženih tablet EU/1/96/022/010 56 obloženih tablet EU/1/96/022/032 70 obloženih tablet EU/1/96/022/038 98 obloženih tablet
Eli Lilly Nederland B.V. Tel: + 31 (0)30 6025800 
Tel: + 31 (0)30 6025800
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1 % and < 1 %). 
Občasno ( ≥ 0.1% in < 1%) so poročali o občasnih povezavah med zdravljenjem z olanzapinom in vensko tromboembolijo.
EU/1/96/022/002 28 coated tablets EU/1/96/022/023 35 coated tablets EU/1/96/022/019 56 coated tablets EU/1/96/022/029 70 coated tablets EU/1/96/022/035 98 coated tablets 
EU/1/96/022/002 28 obloženih tablet EU/1/96/022/023 35 obloženih tablet EU/1/96/022/019 56 obloženih tablet EU/1/96/022/029 70 obloženih tablet EU/1/96/022/035 98 obloženih tablet
ZYPREXA 5 mg coated tablets Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4115”. 
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4115”.
Tablet core 
tablet.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA 10 mg COATED TABLETS: BLISTER FOIL LABEL 
ZYPREXA 10 mg OBLOŽENE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL ON VIAL OF 10 mg POWDER 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNIH OMOTIH ALI DVOJNIH TRAKOVIH
For further information on continued treatment with oral olanzapine (5 to 20 mg daily), see the Summary of Product Characteristics for ZYPREXA coated tablets or ZYPREXA VELOTAB orodispersible tablets. 
Za nadaljnje informacije o vzdrževalnem zdravljenju s peroralnim olanzapinom (5 do 20 mg na dan)
ZYPREXA 2.5 mg coated tablets Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4112”. 
Okrogle, bele, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4112”.
Urinary hesitation11 
Trombocitopenij a11
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ZYPREXA 20 mg COATED TABLETS: BLISTER FOIL LABEL 
ZYPREXA 20 mg OBLOŽENE TABLETE: OZNAKA FOLIJE PRETISNEGA OMOTA
(Perforation to allow health care provider information to be detached) INSTRUCTIONS FOR HEALTH CARE PROFESSIONALS Reconstitution and administration of ZYPREXA Reconstitute ZYPREXA Powder for Solution for Injection only with water for injections. 
(Perforacija, ki omogoča, da zdravstveno osebje odtrga informacije.)
Thrombocytopenia11 
Trombocitope nija11
Date of first authorisation: 1 December 2008 Date of latest renewal: 26 August 2013 
Datum prve odobritve: 1. december 2008 Datum zadnjega podaljšanja: 26. avgust 2013
This medicine should not be used in children and adolescents (< 18 years) because the safety and efficacy have not yet been fully established. 
Tega zdravila se ne sme uporabljati pri otrocih in mladostnikih (< 18 let), ker varnost in učinkovitost še nista bili popolnoma ugotovljeni.
The volume of distribution is 53-93 litres. 
Volumen porazdelitve je 53 do 93 litrov.
The patient should be closely monitored, and the treatment should be symptomatic and supportive. 
Bolnika je treba skrbno nadzorovati, zdravljenje pa mora biti simptomatsko in podporno.
- Patients with high blood pressure 
- Bolniki z visokim krvnim tlakom
Some of these effects may be serious and may require medical attention. 
Nekateri neželeni učinki so lahko hudi in lahko zahtevajo zdravniško pomoč.
None of these increases were associated with identifiable clinical musculoskeletal events. 
Nobeno od teh povečanj ni bilo povezano s prepoznavnimi kliničnimi mišično-skeletnimi pojavi.
This results in an increase in blood pressure. 
Posledica je zvišanje krvnega tlaka.
Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made. 
Trenutno razpoložljivi podatki so opisani v poglavjih 4.8, 5.1 in 5.2 vendar priporočil o odmerjanju ni mogoče dati.
PVC/PE/PVDC/Alu 
BLISTER PVC/PE/PVDC/Al
You can take Ifirmasta with or without food. 
Zdravilo Ifirmasta lahko jemljete s hrano ali brez nje.
The safety and efficacy of Ifirmasta in children aged 0 to 18 has not been established. 
Varnost in učinkovitost zdravila Ifirmasta pri otrocih, starih od 0 do 18 let, nista bili dokazani.
These adverse reactions are derived from spontaneous reports. 
Ti neželeni učinki izhajajo iz spontanih poročil,.
Activated charcoal may be useful in the treatment of overdosage. 
Aktivno oglje je lahko koristno pri zdravljenju preodmerjanja.
If you forget to take Ifirmasta 
Če ste pozabili vzeti zdravilo Ifirmasta
It is important that you continue to take Ifirmasta until your doctor tells you otherwise. 
Pomembno je, da zdravilo Ifirmasta jemljete redno, vse dokler vam zdravnik ne predpiše drugače.
Primary aldosteronism 
Primarni aldosteronizem:
Do not take Ifirmasta - if you are allergic to irbesartan or any of the other ingredients of this medicine (listed in section 6), - if you are more than 3 months pregnant. 
Ne jemljite zdravila Ifirmasta: - če ste alergični na irbesartan ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če ste noseči dlje kot tri mesece.
Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. 
Pri odraslih, ki so bili 8 tednov izpostavljeni odmerkom do 900 mg/dan, niso odkrili toksičnosti.
The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. 
Upočasnitev napredovanja v klinično proteinurijo je bila vidna že v prvih treh mesecih in se je nadaljevala skozi dveletno obdobje.
What you need to know before you take Ifirmasta 
Kaj morate vedeti, preden boste vzeli zdravilo Ifirmasta
Additional information on irbesartan interactions: 
Dodatni podatki o medsebojnem delovanju z irbesartanom:
See also information under the heading “Do not take Ifirmasta”. 
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Ifirmasta”.
Ifirmasta is indicated in adults for the treatment of essential hypertension. 
Zdravilo Ifirmasta je indicirano pri odraslih za zdravljenje esencialne hipertenzije.
The predefined blood pressure goal was ≤ 135/85 mmHg. 
Ciljni krvni tlak je bil ≤ 135/85 mmHg.
Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. 
Vezava na plazemske beljakovine je približno 96-odstotna, vezava na krvne celice pa zanemarljiva.
Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). 
Pri 21 otrocih jo je bilo možno primerjati s farmakokinetiko pri odraslih (12 otrok je bilo starejših od 12 let, 9 otrok je bilo starih od 6 do 12 let).
The frequency of adverse reactions listed below is defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Pogostost v nadaljevanju naštetih neželenih učinkov je opredeljena po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000).
If you experience these, talk to your doctor before attempting to drive or use machines. 
Če se vam to dogaja, se morate posvetovati s svojim zdravnikom, preden nameravate voziti ali upravljati stroje.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6). 
Drugo in tretje trimesečje nosečnosti (gl. poglavji 4.4 in 4.6).
What Ifirmasta is and what it is used for 
Kaj je zdravilo Ifirmasta in za kaj ga uporabljamo
All of these changes were considered to be caused by the pharmacological action of irbesartan. 
Vse te spremembe naj bi bile posledica farmakološkega delovanja irbesartana.
Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3000 
Filmska obloga polivinilalkohol titanov dioksid (E171) makrogol 3000 smukec
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
V vsaki skupini so neželeni učinki navedeni po padajoči resnosti.
The major circulating metabolite is irbesartan glucuronide (approximately 6%). 
Glavni presnovek v obtoku je irbesartan glukuronid (približno 6 %).
Other medicines and Ifirmasta 
Druga zdravila in zdravilo Ifirmasta
The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively. 
Skupni telesni in ledvični očistek je 157 do 176 oz. 3 do 3,5 ml/min.
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. 
Epidemiološke raziskave niso pokazale teratogenega učinka pri nosečnicah, ki so bile v prvem trimesečju nosečnosti izpostavljene zaviralcem ACE, vendar pa nekoliko povečanega tveganja ni možno izključiti.
However, occasionally dizziness or weariness may occur during treatment of high blood pressure. 
Občasno se lahko med zdravljenjem visokega krvnega tlaka pojavita omotica ali utrujenost.
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. 
Bolniki s primarnim aldosteronizmom se na splošno ne odzivajo na antihipertenzive, ki delujejo tako, da zavirajo sistem renin-angiotenzin.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Pharmacotherapeutic group: angiotensin II antagonist, plain, ATC code: C09CA04. 
Farmakoterapevtska skupina: antagonisti angiotenzina II, enokomponentna zdravila, oznaka ATC: C09CA04.
Irbesartan does not require metabolic activation for its activity. 
Irbesartan za svojo učinkovitost ne potrebuje metabolične aktivacije.
Results showed that Cmax, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. 
Rezultati so pokazali, da so bili maksimalna koncentracija, AUC in očistek primerljivi rezultatom pri tistih odraslih, ki so dobivali 150 mg irbesartana na dan.
If you take more Ifirmasta than you should If you accidentally take too many tablets, contact your doctor immediately. 
Če ste vzeli večji odmerek zdravila Ifirmasta, kot bi smeli Če ste pomotoma vzeli preveč tablet, takoj pokličite svojega zdravnika.
(It is also better to avoid Ifirmasta in early pregnancy - see pregnancy section), - if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. 
(Jemanju zdravila Ifirmasta se je bolje izogniti tudi med zgodnjo nosečnostjo - glejte poglavje o nosečnosti), - če imate sladkorno bolezen ali okvarjeno delovanje ledvic in se zdravite z zdravilom za znižanje krvnega tlaka, ki vsebuje aliskiren.
You may need to have blood checks if you take: - potassium supplements, - salt substitutes containing potassium, - potassium-sparing medicines (such as certain diuretics), - medicines containing lithium. 
Morda bodo potrebne krvne preiskave, če jemljete: - dodatke kalija - nadomestke soli, ki vsebujejo kalij - zdravila, ki varčujejo s kalijem (kot so nekateri diuretiki) - zdravila, ki vsebujejo litij
Ifirmasta at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. 
Na splošno zagotavlja 150 mg zdravila Ifirmasta enkrat na dan boljši 24-urni nadzor krvnega tlaka kot 75 mg.
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. 
Irbesartan je močan peroralno delujoč selektivni antagonist receptorjev za angiotenzin II (tip AT1).
Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dose adjustment is not usually necessary for older people. 
Čeprav je treba pri bolnikih, ki so starejši od 75 let, pretehtati možnost uporabe začetnega odmerka po 75 mg, prilagajanje odmerka običajno ni potrebno.
Irbesartan lowers blood pressure with minimal change in heart rate. 
Irbesartan znižuje krvni tlak ob minimalni spremembi srčnega utripa.
Your doctor may need to change your dose and/or to take other precautions: - If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Ifirmasta” and “Warnings and precautions”). 
Zdravnik vam bo morda moral spremeniti odmerek in/ali upoštevati druge previdnostne ukrepe: - Če jemljete zaviralec ACE ali aliskiren (glejte tudi informacije pod naslovoma "Ne jemljite zdravila Ifirmasta" in "Opozorila in previdnostni ukrepi").
C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. 
C irbesartana prispeva 80 do 85 % radioaktivnosti v plazemskem obtoku nespremenjeni irbesartan.
What Ifirmasta is and what it is used for What you need to know before you take Ifirmasta How to take Ifirmasta 
Kaj je zdravilo Ifirmasta in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Ifirmasta Kako jemati zdravilo Ifirmasta Možni neželeni učinki
In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. 
Raziskave in vitro kažejo, da se irbesartan primarno oksidira s citokromom P450, encimom CYP2C9; izoencim CYP3A4 ima zanemarljiv učinek.
In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed. 
Pri 1,7 % bolnikov z visokim krvnim tlakom z napredovalo diabetično ledvično boleznijo, ki so jih zdravili z irbesartanom, so opazili zmanjšanje vrednosti hemoglobina*, ki pa ni bilo klinično pomembno.
Diuretics and other antihypertensive agents: 
Diuretiki in drugi antihipertenzivi:
In particular, they appeared less favourable in women and non-white subjects (see section 5.1). 
Zdi se, da so manj ugodni pri ženskah in pri temnopoltih bolnikih (gl. poglavje 5.1).
At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. 
Po 24 urah je znižanje krvnega tlaka še vedno znašalo 60 do 70 % največjega diastoličnega in sistoličnega odziva na priporočeni odmerek.
The usual dose is 150 mg once a day (two tablets a day). 
Običajni odmerek je 150 mg enkrat na dan (dve tableti).
Read the package leaflet before use. 
za peroralno uporabo Pred uporabo preberite priloženo navodilo!
After withdrawal of therapy, blood pressure gradually returns toward baseline. 
Po ukinitvi zdravila se krvni tlak postopoma vrne na začetno vrednost.
However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years. 
Vendar pa je treba pretehtati možnost uvajanja zdravljenja s 75 mg, zlasti pri bolnikih na hemodializi in pri starejših od 75 let.
The most likely manifestations of overdosage are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. 
Kot posledico prevelikega odmerjanja je najverjetneje pričakovati hipotenzijo in tahikardijo, lahko pa se pojavi tudi bradikardija.
Blister (PVC/PE/PVDC/Alu): 56 x 1 film-coated tablets in perforated unit dose blisters in box. 
Pretisni omot (PVC/PE/PVDC/Al): 56 x 1 filmsko obloženih tablet perforiranih blistrih, v škatli.
If the combination proves necessary, careful monitoring of serum lithium levels is recommended. 
Če se pokaže, da so potrebne, priporočamo skrbno spremljanje serumske koncentracije litija.